## **İŞBANK**

## TÜRKİYE İŞ BANKASI A.Ş. U.S.\$5,000,000,000 Global Medium Term Note Program

This supplement (this "Supplement") is supplemental to, and must be read in conjunction with, the Base Prospectus dated July 17, 2014 (the "Base Prospectus") prepared by Türkiye İş Bankası A.Ş. (the "Issuer") under the Issuer's global medium term note program. Capitalized terms used but not otherwise defined herein shall have the meaning ascribed thereto in the Base Prospectus.

This Supplement has been approved by the Central Bank of Ireland, as competent authority under Directive 2003/71/EC as amended (including the amendments made by Directive 2010/73/EU) (the "*Prospectus Directive*"). The Central Bank of Ireland only approves this Supplement as meeting the requirements imposed under Irish and EU law pursuant to the Prospectus Directive. This document constitutes a supplement for the purposes of Article 16 of the Prospectus Directive and has been prepared and published for the purposes of incorporating the latest financial statements into the Base Prospectus.

A copy of each of: (a) the consolidated BRSA financial statements of the Group as of and for the six month period ended June 30, 2014 (including any notes thereto, the "Group's New BRSA Financial Statements") and (b) the unconsolidated BRSA financial statements of the Issuer as of and for the six month period ended June 30, 2014 (including any notes thereto, the "Issuer's New BRSA Financial Statements" and, with the Group's New BRSA Financial Statements, the "New BRSA Financial Statements") have been filed with the Central Bank of Ireland and, by means of this Supplement, are incorporated by reference into, and form part of, the Base Prospectus. Copies of the New BRSA Financial Statements can be obtained without charge from the registered office of the Issuer and from the Issuer's website: (i) with respect to the Group's New BRSA Financial Statements, http://www.isbank.com.tr/EN/about-isbank/investor-relations/publications-andresults/financial-statements/Pages/financial-statements.aspx, and (ii) with respect to the Issuer's New BRSA Financial http://www.isbank.com.tr/EN/about-isbank/investor-relations/publications-and-results/financial-Statements, statements/Pages/financial-statements.aspx (such website is not, and should not be deemed to constitute, a part of, or be incorporated into, this Supplement or the Base Prospectus). The New BRSA Financial Statements, each of which is in English, were prepared as convenience translations of the corresponding Turkish language financial statements (which translations the Issuer confirms were direct and accurate). The New BRSA Financial Statements were not prepared for the purpose of their incorporation by reference into the Base Prospectus.

Statements contained herein shall, to the extent applicable and whether expressly, by implication or otherwise, be deemed to modify or supersede statements set out in, or previously incorporated by reference into, the Base Prospectus. Where there is any inconsistency between the information contained in (or incorporated by reference into) the Base Prospectus and this Supplement, the information contained in (or incorporated by reference into) this Supplement shall prevail.

Except as disclosed in the New BRSA Financial Statements incorporated by reference into the Base Prospectus pursuant to this Supplement, there has been no: (a) significant new factor, material mistake or inaccuracy relating to the information included in the Base Prospectus since the publication of the Base Prospectus and (b) significant change in the financial or trading position of either the Group or the Issuer since June 30, 2014.

The Issuer accepts responsibility for the information contained herein. To the best of the knowledge and belief of the Issuer (which has taken all reasonable care to ensure that such is the case), the information contained herein is in accordance with the facts and contains no omission likely to affect the import of such information. None of the Dealers or the Arrangers make any representation, express or implied, or accept any responsibility, for the contents hereof or any information incorporated by reference into this Supplement.